Remove Labelling Remove Packaging Remove Webinar
article thumbnail

RxSource optimizes clinical labeling process with PRISYM 360 cloud-based solution

pharmaphorum

For PRISYM ID client RxSource , a Global Clinical Trial Supplies Specialist, it means being ready to partner with sponsor companies to get everything set up for a clinical trial within a week, including packaging and labeling. To find out more about the webinar and to register, visit [link] .

article thumbnail

November 2023 Newsletter

Safe Biologics

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

September 2023 Newsletter

Safe Biologics

View the full webinar here or watch individual segments linked below. 6 would prevent the HHS Secretary from requiring a switching study as part of the data package to receive the interchangeable designation. View ASBM’s recent webinar on the IRA’s effects here. However, S.6 ASBM surveys of U.S. Read it here.

article thumbnail

October 2023 Newsletter

Safe Biologics

REMINDER: FDA Draft Guidance Would Remove Interchangeability Statement from Interchangeable Biosimilars Comments Due November 17th On September 15th, the Food and Drug Administration (FDA) released draft guidance removing the interchangeability statement from the product label/package insert. Watch clips from the webinar here.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

WebinarsWebinars, whether live streamed or on-demand, can be used for communication with HCPs, HCOs, and POs. A company is responsible for the content of webinars and should take reasonable steps to ensure the audience is targeted and well defined.